跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 206 条关于
“Guangdong”
全部
206
临床试验
30
药物
89
机构
37
资讯
50
去年
Everest Medicines Launches VELSIPITY® for Ulcerative Colitis in Greater Bay Area
去年
Everest Medicines Launches VELSIPITY® for Ulcerative Colitis in Greater Bay Area
2个月前
Ivonescimab Outperforms Keytruda in Head-to-Head Phase III Trial, Signaling China's Biotech Ascent from the Greater Bay Area
5个月前
SBP Group's M701 Bispecific Antibody Receives NDA Acceptance for Malignant Ascites Treatment
2年前
Fulzerasib Shows Promise in KRAS G12C-Mutated NSCLC: Updated Phase 2 Results
2个月前
China Expands Personalized Cosmetic Service Pilot to 23 Provincial-Level Regions
去年
EUDA Secures Distribution Rights for T-Cell Immunotherapy in Malaysia at $8,000 Per Treatment
去年
Osimertinib Plus Savolitinib Shows Promise in MET-Aberrant EGFR-Mutant NSCLC
3个月前
China-Nexus Espionage Group UNC6508 Targeted North American Medical Research Networks in Multiyear Cyber Campaign
去年
IgA Nephropathy Pipeline Shows Strong Growth with 30+ Therapies in Development Across Multiple Clinical Stages
第 1 页,共 5 页
上一页
下一页